[go: up one dir, main page]

WO2002029403A1 - Gata-3 expression inhibitor and method of screening the same - Google Patents

Gata-3 expression inhibitor and method of screening the same Download PDF

Info

Publication number
WO2002029403A1
WO2002029403A1 PCT/JP2001/008564 JP0108564W WO0229403A1 WO 2002029403 A1 WO2002029403 A1 WO 2002029403A1 JP 0108564 W JP0108564 W JP 0108564W WO 0229403 A1 WO0229403 A1 WO 0229403A1
Authority
WO
WIPO (PCT)
Prior art keywords
gata
cells
substance
expression inhibitor
screening
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2001/008564
Other languages
French (fr)
Japanese (ja)
Inventor
Shoji Furusako
Yutaka Kato
Takaaki Negishi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mochida Pharmaceutical Co Ltd
Original Assignee
Mochida Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mochida Pharmaceutical Co Ltd filed Critical Mochida Pharmaceutical Co Ltd
Priority to AU2001290316A priority Critical patent/AU2001290316A1/en
Publication of WO2002029403A1 publication Critical patent/WO2002029403A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

A method of efficiently finding out a substance inhibiting the Th2 shift of helper T cells mediated by binding to AhR, a substance acting on the IgE class switch of B cells to thereby inhibit the IgE production from B cells and/or a substance inhibiting an inflammatory reaction accompanied by the differentiation/migration or infiltration of eosinophils, and a substance modifying the expression of GATA-3 of T cells; and a GATA-3 expression inhibitor.
PCT/JP2001/008564 2000-10-02 2001-09-28 Gata-3 expression inhibitor and method of screening the same Ceased WO2002029403A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2001290316A AU2001290316A1 (en) 2000-10-02 2001-09-28 Gata-3 expression inhibitor and method of screening the same

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2000302779 2000-10-02
JP2000-302779 2000-10-02

Publications (1)

Publication Number Publication Date
WO2002029403A1 true WO2002029403A1 (en) 2002-04-11

Family

ID=18784079

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2001/008564 Ceased WO2002029403A1 (en) 2000-10-02 2001-09-28 Gata-3 expression inhibitor and method of screening the same

Country Status (2)

Country Link
AU (1) AU2001290316A1 (en)
WO (1) WO2002029403A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007522114A (en) * 2004-01-12 2007-08-09 ナトロジェン・セラピューティクス・インコーポレーテッド Treatment of inflammation-related diseases

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5547684A (en) * 1978-09-29 1980-04-04 Takeda Chem Ind Ltd Preparation of antitrichophytosis substance
JPH11501807A (en) * 1995-03-03 1999-02-16 メレニウム ファーマシューティカルズ，インコーポレーテッド Compositions and methods for the treatment and diagnosis of immune disorders
JP2000510333A (en) * 1996-04-23 2000-08-15 プレジデント アンド フェロウズ オブ ハーバード カレッジ Methods and compositions for controlling T cell subsets by modulating factor activity

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5547684A (en) * 1978-09-29 1980-04-04 Takeda Chem Ind Ltd Preparation of antitrichophytosis substance
JPH11501807A (en) * 1995-03-03 1999-02-16 メレニウム ファーマシューティカルズ，インコーポレーテッド Compositions and methods for the treatment and diagnosis of immune disorders
JP2000510333A (en) * 1996-04-23 2000-08-15 プレジデント アンド フェロウズ オブ ハーバード カレッジ Methods and compositions for controlling T cell subsets by modulating factor activity

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DATABASE GENBANK [online] 26 March 2000 (2000-03-26), BIRREN B. ET AL.: "Homo sapiens chromosome 21, clone RP11-489h3", XP002906348, Database accession no. AC058800 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007522114A (en) * 2004-01-12 2007-08-09 ナトロジェン・セラピューティクス・インコーポレーテッド Treatment of inflammation-related diseases
JP2012176956A (en) * 2004-01-12 2012-09-13 Natrogen Therapeutics Internatl Inc Therapy of disease related to inflammation
JP2015071626A (en) * 2004-01-12 2015-04-16 ナトロジェン・セラピューティクス・インターナショナル，インコーポレーテッド Therapy of inflammation-related disease

Also Published As

Publication number Publication date
AU2001290316A1 (en) 2002-04-15

Similar Documents

Publication Publication Date Title
WO2002042486A3 (en) Methods for detection of a nucleic acid by sequential amplification
ZA200301039B (en) Inhibitors of alpha4 mediated cell adhesion.
WO2004097838A3 (en) Memory-circuit arrangement and method for the production thereof
DE69828803D1 (en) TECHNIQUES AND SYSTEMS FOR THE DETECTION OF ANALYTES
DE60135912D1 (en) DETECTION OF HYBRIDIZATION OF NUCLEIC ACIDS BY FLUORESCENCE POLARIZATION
WO2003059296A3 (en) Compositions comprising collagen and metalloprotease inhibitors
AU2001245945A1 (en) Detection kits, such as nucleic acid arrays, for detecting the expression of 10,000 or more drosophila genes and uses thereof
WO2001048183A3 (en) Improvements relating to double-stranded rna inhibition
WO2004107408A3 (en) Modular array defined by standard cell logic
AU2002233225A1 (en) Bioanalytical reagent, method for production thereof, sensor platforms and detection methods based on use of said bioanalytical reagent
WO2005019495A3 (en) Control system for a sputtering system
WO1999015129A3 (en) SELECTIVE cPLA2 INHIBITORS
WO2002004488A3 (en) Nucleic acid binding polypeptides
AU2002354696A1 (en) Method for purifying an enzyme, a purified enzyme produced thereby, and use of this enzyme
WO2003048383A3 (en) Effectors of innate immunity
WO2003089606A3 (en) Thermostable dna polymerases and methods of making same
WO2001055708A3 (en) Method of processing a sample containing at least one biological element
DE69915686D1 (en) AMIDINODERIVATES AND THEIR USE AS THROMBIN INHIBITORS
WO2002029403A1 (en) Gata-3 expression inhibitor and method of screening the same
WO2003086716A8 (en) Robot system and controller
AU4719699A (en) Substituted quinoxalin-2(1h)-ones useful as hiv reverse transcriptase inhibitors
WO2001096592A3 (en) Reverse detection for identification and/or quantification of nucleotide target sequences on biochips
DE60217963D1 (en) Forward amplifying circuit
TR200003589T2 (en) Biologically active composition.
WO2002004657A3 (en) Screening method

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP